22 MAR 2024 Pharmaceuticals Otsuka Pharmaceutical's subsidiaries in Indonesia awarded Exemplar Award by Ending Workplace Tuberculosis (EWTB) for Otsuka's efforts to eliminate tuberculosis
22 MAR 2024 Pharmaceuticals Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment
18 AUG 2022 Pharmaceuticals PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
6 OCT 2021 Pharmaceuticals Otsuka Announces Approval in EU of Pediatric, 25 mg Dispersible-Tablet Formulation of Deltyba™ for Multidrug-Resistant Tuberculosis
10 AUG 2021 Pharmaceuticals Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaquiline
25 MAY 2020 Pharmaceuticals Deltyba® (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)
27 FEB 2020 Pharmaceuticals First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis
23 MAR 2018 Pharmaceuticals Otsuka's DELTYBA Approved in China for the Treatment of Multidrug-resistant Tuberculosis
29 JAN 2018 Pharmaceuticals Otsuka Awarded Grant to Advance Development of Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid
14 DEC 2017 Pharmaceuticals Otsuka Pharmaceutical Co., Ltd. Receives the Japan Medical R&D Grand Prize for Development of Delamanid, a Drug for Multidrug-resistant Tuberculosis Japanese Government Grants Award for the First Time
24 AUG 2017 Pharmaceuticals Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (DeltybaTM) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries (PDF: 467.1 KB)
18 JUL 2017 Pharmaceuticals Otsuka and R-Pharm Announce Licensing Agreement to Commercialize DeltybaTM (Delamanid) for Multidrug-Resistant Tuberculosis (MDR-TB) in Russia and CIS Countries (PDF: 99.9 KB)
1 JUN 2017 Pharmaceuticals Otsuka to Continue Commitment to Support the Global Health Innovative Technology Fund (GHIT Fund)
21 APR 2016 Pharmaceuticals Otsuka receives two commendations by the Japanese Government for the development of an anti-tuberculosis agent and an aquaretic/ADPKD treatment
25 FEB 2016 Pharmaceuticals Otsuka Announces Worldwide Access Plan for Delamanid with Stop TB Partnership's Global Drug Facility
16 JUL 2015 Pharmaceuticals Efficacy Results of Otsuka's Delamanid (Deltyba™) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Published in the New England Journal of Medicine
19 MAR 2015 Pharmaceuticals The Union and Otsuka Open Nominations for 2nd Global TB Research & Innovation Award
8 SEP 2014 Pharmaceuticals A Change in the Treatment of Multidrug-Resistant Tuberculosis Begins New Antituberculosis Drug Deltyba® in 50 mg Tablets, Available to Patients in Japan Starting September 26
4 JUL 2014 Pharmaceuticals After 40 Years, A New Drug For The Treatment Of Tuberculosis In Japan Deltyba® (delamanid) Is The First Drug Approved In Japan Specifically For Pulmonary Multidrug-Resistant Tuberculosis (MDR-TB)
25 NOV 2013 Pharmaceuticals CHMP Recommends Otsuka's Deltyba™ (delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)
27 MAR 2013 Pharmaceuticals Otsuka's Novel Treatment for Multidrug-Resistant Tuberculosis, Delamanid, Submitted For Regulatory Approval in Japan -- Half Century Since Last Drug Was Approved in Japan for Tuberculosis
7 JUN 2012 Pharmaceuticals The New England Journal of Medicine Publishes Efficacy Results of Otsuka's Delamanid for Multidrug-Resistant Tuberculosis New Research Shows 53% Increase in Sputum Culture Conversion (SCC) After Two Months
17 MAY 2011 Pharmaceuticals Otsuka Pharmaceutical Establishes Subsidiary, Otsuka SA, to Facilitate Public Advocacy for the Company's Global Tuberculosis Program